Arca Biopharma said today it extended a US, Canadian and European clinical trial collaboration deal with medtech giant Medtronic (NYSE:MDT) for an additional year, now slated to continue until April 2019.
Through the deal, Medtronic will support clinical trial use of its monitoring devices, collection of managed atrial fibrillation burden data and managed analysis of cardiac rhythms with Medtronic devices, Westminster, Colo.-based Arca Biopharma said.
Data will be collected with either previously implanted cardiac resynchronization or defibrillation devices or newly implanted Reveal loop recorders, Arca added.
“Medtronic has been a terrific partner in exploring and understanding atrial fibrillation in a clinical trial setting. We are excited to extend our collaboration as we continue analysis of the trial data from Genetic-AF and consider potential future development plans for Gencaro,” Arca prez & CEO Dr. Michael Bristow said in a press release.
Last week, Medtronic said it launched its OptiSphere embolization spheres designed for embolization of hypervascular tumors.